Lipid levels and cardiovascular risk in elderly women: a general population study of the effects of hormonal treatment and lipid-lowering agents

References

• Moghadasian M H. Statins and menopause. Drugs 2002; 62: 2421–2431
   PubMed Web of Science ®Google Scholar
• Nerbrand C, Lidfeldt J, Nyberg P, Schersten B, Samsioe G. Serum lipids and lipoproteins in relation to endogenous and exogenous female sex steroids and age. The Women's Health in the Lund Area (WHILA) study. Maturitas 2004; 48: 161–169
   PubMed Web of Science ®Google Scholar
• LaRosa J C. Lipids and cardiovascular disease: do the findings and therapy apply equally to men and women?. Womens Health Issues 1992; 2: 102–111, discussion 111–13
   PubMedGoogle Scholar
• Godsland I F. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein(a) concentrations: analysis of studies published from 1974–2000. Fertil Steril 2001; 75: 898–915
   PubMed Web of Science ®Google Scholar
• Nelson H D, Humphrey L L, Nygren P, Teutsch S M, Allan J D. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288: 872–881
   PubMed Web of Science ®Google Scholar
• Anderson G L, Limacher M, Assaf A R, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701–1712
   PubMed Web of Science ®Google Scholar
• Rossouw J E, Anderson G L, Prentice R L, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Manson J E, Hsia J, Johnson K C, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003; 349: 523–534
   PubMed Web of Science ®Google Scholar
• Prentice R L, Langer R, Stefanick M L, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005; 162: 404–414
   PubMed Web of Science ®Google Scholar
• Miyagawa K, Rosch J, Stanczyk F, Hermsmeyer K. Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 1997; 3: 324–327
   PubMed Web of Science ®Google Scholar
• Otsuki M, Saito H, Xu X, et al. Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 2001; 21: 243–248
   PubMed Web of Science ®Google Scholar
• Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Different effects of oral conjugated equine estrogen and transdermal estrogen replacement therapy on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 2002; 106: 1771–1776
   PubMed Web of Science ®Google Scholar
• Oger E, Alhenc-Gelas M, Lacut K, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women. A randomized trial. Arterioscler Thromb Vasc Biol 2003; 17: 17
   Google Scholar
• Scarabin P Y, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 3071–3078
   PubMed Web of Science ®Google Scholar
• Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001; 85: 619–625
   PubMed Web of Science ®Google Scholar
• Decensi A, Omodei U, Robertson C, et al. Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. Circulation 2002; 106: 1224–1228
   PubMed Web of Science ®Google Scholar
• de Kraker A T, Kenemans P, Smolders R G, Kroeks M V, van der Mooren M J. The effects of 17 beta-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a). Maturitas 2004; 49: 253–263
   PubMed Web of Science ®Google Scholar
• Clarke S C, Kelleher J, Lloyd-Jones H, Slack M, Schofiel P M. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. Br J Obstet Gynaecol 2002; 109: 1056–1062
   Google Scholar
• The 3C Study Group. Vascular factors and risk of dementia: design of the three city study and baseline characteristics of the study population. Neuroepidemiology 2003; 22: 316–325
   PubMed Web of Science ®Google Scholar
• World Health Organisation. International Classification of DiseasesTenth Revision. WHO, Geneva 1992
   Google Scholar
• Friedewald W T, Levy R I, Fredrickson D S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502
   PubMed Web of Science ®Google Scholar
• Dufouil C, Richard F, Fievet N, et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology 2005; 64: 1531–1538
   PubMed Web of Science ®Google Scholar
• Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497
   PubMed Web of Science ®Google Scholar
• Davidson M H, Testolin L M, Maki K C, von Duvillard S, Drennan K B. A comparison of estrogen replacement, pravastatin, and combined treatment for the management of hypercholesterolemia in postmenopausal women. Arch Intern Med 1997; 157: 1186–1192
   PubMed Web of Science ®Google Scholar
• Darling G M, Johns J A, McCloud P I, Davis S R. Concurrent use of simvastatin and estrogen–progestin therapy compared with each therapy alone for hypercholesterolemia in postmenopausal women. Climacteric 1999; 2: 181–188
   PubMedGoogle Scholar
• Herrington D M, Werbel B L, Riley W A, Pusser B E, Morgan T M. Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease. J Am Coll Cardiol 1999; 33: 2030–2037
   PubMed Web of Science ®Google Scholar
• Davis S R, Goldstat R, Newman A, et al. Differing effects of low-dose estrogen–progestin therapy and pravastatin in postmenopausal hypercholesterolemic women. Climacteric 2002; 5: 341–350
   PubMed Web of Science ®Google Scholar
• Nerbrand C, Nyberg P, Nordstrom L, Samsioe G. Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides. Maturitas 2002; 42: 55–62
   PubMed Web of Science ®Google Scholar
• Sanada M, Nakagawa H, Kodama I, Sakasita T, Ohama K. Three-year study of estrogen alone versus combined with progestin in postmenopausal women with or without hypercholesterolemia. Metabolism 2000; 49: 784–789
   PubMed Web of Science ®Google Scholar
• Darling G M, Johns J A, McCloud P I, Davis S R. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997; 337: 595–601
   PubMed Web of Science ®Google Scholar
• Despres J P, Lemieux I, Salomon H, Delaval D. Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial. J Intern Med 2002; 251: 490–499
   PubMed Web of Science ®Google Scholar
• Seed M. The choice of hormone replacement therapy or statin therapy in the treatment of hyperlipidemic postmenopausal women. Atheroscler Suppl 2002; 3: 53–63
   PubMed Web of Science ®Google Scholar
• Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2005; 114: 448–454
   PubMed Web of Science ®Google Scholar
• Farquhar C M, Marjoribanks J, Lethaby A, Lamberts Q, Suckling J A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2005, CD004143
   Web of Science ®Google Scholar
• Skouby S O, Al-Azzawi F, Barlow D, et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 2005; 51: 8–14
   PubMed Web of Science ®Google Scholar
• Canonico M, Straczek C, Oger E, Plu-Bureau G, Scarabin P Y. Postmenopausal hormone therapy and cardiovascular disease: an overview of main findings. Maturitas 2006; 54: 372–379
   PubMed Web of Science ®Google Scholar
• Scarabin P Y, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428–432
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115: 840–845
   PubMed Web of Science ®Google Scholar